Literature DB >> 1921148

Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.

G L Warwick1, C J Packard, T Demant, D K Bedford, J M Boulton-Jones, J Shepherd.   

Abstract

Although hyperlipidemia is a well recognized complication of the nephrotic syndrome, the precise disturbances of lipoprotein metabolism which cause the elevated plasma lipid and lipoprotein concentrations have not been clearly defined in humans. This study examines the metabolism of apolipoprotein B-containing lipoproteins in patients with nephrotic-range proteinuria and in healthy controls. Two radioiodinated tracers of very low density lipoproteins (VLDL1, Sf60 to 400, and VLDL2, Sf20 to 60), were used to trace the metabolism of apolipoprotein B through the delipidation cascade from very low density lipoproteins (VLDL) to low density lipoproteins (LDL). The data from the apoB specific radioactivity curves and the pool sizes of apoB in four subfractions were analyzed by a multicompartmental modeling procedure using the SAAM 30 program. The main findings in the nephrotic group were: 1.) a consistent decrease in the fractional rate of apoB transfer from VLDL1----VLDL2 (median values-nephrotic 0.92 pools/day vs. controls 3.66, P less than 0.02) and from VLDL2----IDL (1.49 vs. 2.74, P less than 0.05); 2.) increased secretion of apoB into VLDL2 (14.5 mg/kg/day vs. 4.2, P less than 0.02); 3.) a trend towards decreased removal of IDL and LDL attributable to a defect in LDL receptor-mediated removal as previously shown (Metabolism 39:187-192, 1990). These findings suggest that catabolic defects of the apo B-containing lipoproteins are as important as increased hepatic synthesis in the pathogenesis of nephrotic hyperlipidemia in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1921148     DOI: 10.1038/ki.1991.190

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 3.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

4.  Graded effects of proteinuria on HDL structure in nephrotic rats.

Authors:  Gregory C Shearer; John W Newman; Bruce D Hammock; George A Kaysen
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

5.  Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies.

Authors:  Tian-Biao Zhou; Yuan-Han Qin; Hui-Ling Xu
Journal:  Mol Biol Rep       Date:  2012-07-04       Impact factor: 2.316

Review 6.  Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Authors:  Mona Khurana; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2015-03-24       Impact factor: 3.714

7.  Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease.

Authors:  Xuewen Wang; Sharina Belani; Daniel W Coyne; Elisa Fabbrini; Dominic N Reeds; Bruce W Patterson; Bettina Mittendorfer; Samuel Klein
Journal:  Cardiorenal Med       Date:  2012-01-26       Impact factor: 2.041

8.  A case of membranous glomerulonephritis presenting as pulmonary embolism and acute hyperlipidaemia.

Authors:  A J Hartland; P D Giles; J E Bridger; W Simmons
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

9.  Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.

Authors:  Seungyeup Han; Nosratola D Vaziri; Pavan Gollapudi; Vincent Kwok; Hamid Moradi
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

10.  Patterns of dyslipidemia amongst hypertensive patients in Abuja, North Central Nigeria.

Authors:  Henry Chijioke Onyegbutulem; Dilli Dogo; Francis Alu; Musa Dankyau; David Samuel Olorunfemi; Faruk Mustapha Abdullahi; Isaac Olubanji Akerele; Nafisah Ja'afar Bala; Ugo Nnenna Ibeabuchi; Maimuna Onyi Mohammed
Journal:  Pan Afr Med J       Date:  2021-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.